{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naprosyn%C2%AE", "query": { "intervention": "Naprosyn®" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naprosyn%C2%AE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T12:30:23.336Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01165307", "title": "Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Menorrhagia" ], "interventions": [ { "name": "Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills", "type": "DRUG" }, { "name": "Naproxen sodium pills", "type": "DRUG" }, { "name": "NovaSure® Radiofrequency Endometrial Ablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Abimbola Famuyide", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "30 Years to 55 Years · Female only" }, "enrollment_count": 77, "start_date": "2009-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01165307" }, { "nct_id": "NCT00573170", "title": "TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine Disorders", "Migraine, Acute" ], "interventions": [ { "name": "TREXIMET®", "type": "DRUG" }, { "name": "Butalbital-containing Combination Medications (BCM)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 375, "start_date": "2008-02", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2010-12-29", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 107, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 94 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573170" }, { "nct_id": "NCT00969449", "title": "Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "Naproxen Sodium, (BAY H6689)", "type": "DRUG" }, { "name": "Naprelan, (BAY H6689)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2009-04", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00969449" }, { "nct_id": "NCT00807846", "title": "A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Arthritis, Juvenile Rheumatoid" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 201, "start_date": "2009-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 18, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00807846" }, { "nct_id": "NCT01712009", "title": "NOLAN: Naproxen or Loratadine and Neulasta", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Pain in Stage I - III Breast Cancer" ], "interventions": [ { "name": "Naproxen", "type": "DRUG" }, { "name": "Loratadine", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 600, "start_date": "2012-11-01", "completion_date": "2015-03-18", "has_results": true, "last_update_posted_date": "2018-01-30", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 83, "location_summary": "Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712009" }, { "nct_id": "NCT02451748", "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lab Work", "type": "OTHER" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)", "type": "DRUG" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Medrol", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "humira", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-08", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451748" }, { "nct_id": "NCT01063920", "title": "Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "LT-NS001", "type": "DRUG" }, { "name": "Naprosyn®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Logical Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "45 Years to 80 Years" }, "enrollment_count": 534, "start_date": "2010-02", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2011-01-24", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01063920" }, { "nct_id": "NCT00650455", "title": "Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "valdecoxib", "type": "DRUG" }, { "name": "naproxen", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 489, "start_date": "2003-02", "completion_date": "2005-01", "has_results": false, "last_update_posted_date": "2008-07-21", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00650455" }, { "nct_id": "NCT00780325", "title": "Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "CG100649 (2 mg)", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Placebo capsules", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "CG100649 (8 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 26, "start_date": "2008-10", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00780325" }, { "nct_id": "NCT00594854", "title": "Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Ulcer" ], "interventions": [ { "name": "PN400 (VIMOVO)", "type": "DRUG" }, { "name": "Diclofenac/Misoprostol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "POZEN", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2007-09", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2010-09-22", "last_synced_at": "2026-09-05T12:30:23.336Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594854" } ] }